Based on the hitherto published reports and the current case, combining of EGFR- and ALK-TKI may be an effective treatment in EGFR-mutated NSCLC with ALK-fusion acquired on the EGFR-TKI therapy. Here, ALK is linked to non-small cell lung carcinoma.